EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios

<i>Epidermal growth factor receptor</i> (<i>EGFR</i>) exon 20 insertion mutations account for a tenth of all <i>EGFR</i> mutations in lung cancers. An important unmet clinical need is the identification of EGFR exon 20 insertion mutants that can respond to multiple classes of approved EGFR-TKIs. We...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ikei S. Kobayashi, Hollis Viray, Deepa Rangachari, Susumu S. Kobayashi, Daniel B. Costa
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2021-12-01
Edice:	Cells
Témata:	lung cancer EGFR exon 20 insertion D770>GY afatinib dacomitinib poziotinib
On-line přístup:	https://www.mdpi.com/2073-4409/10/12/3561
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!